North American Vaccine/Abbott Certiva
Executive Summary
Labeling for DTaP vaccine states that it is recommended for four-dose schedule in diphtheria-tetanus-pertussis series, or to complete the series in children who have received one or two doses of whole-cell DTP vaccines. It is also recommended as the fifth dose in children who have received four whole-cell doses or three whole-cell doses followed by a dose of Certiva. "At this time, there are no data to establish the frequency of adverse events following a fifth dose of Certiva in children who previously received four doses of Certiva," labeling states. North American Vaccine is conducting a five-consecutive dose safety trial ("The Pink Sheet" Aug. 3, p. 3)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth